As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Dr. Bogenschutz presents quantitative findings from a psilocybin trial for alcohol use disorder, showing reduced alcohol craving and improved mood and cognition. Dr. Agin-Liebes discusses qualitative results on self-awareness and
Gabrielle Agin-Liebes
Psychedelic-assisted therapy's history, Bill W's admiration, and the need for peer support group understanding are discussed in relation to sobriety, recovery, and psychedelics.
Kevin Franciotti, Reilly Capps, Celeste Alvarez, Danielle Nova, Rick Barnett, Juliana Mulligan
Psilocybin trial for advanced cancer patients will compare effects of 25mg dose to 1mg placebo on anxiety, depression, and existential distress, using psychotherapy to assess efficacy and psychological mechanisms.
Artificial Intelligence and psychedelics share complexities as powerful tools impacting humanity's reality and choices. Understanding their potential and regulating them ethically are urgent imperatives for positive impact.
Alexander Beiner, De Kai
Panelists from Zendo Project, Fireside Project, Kosmicare, and Anashim Tovim discuss harm reduction strategies in the psychedelic ecosystem, emphasizing innovation, compassion, and scientific expertise in diverse settings. They provide case
Joshua White, Daniel E Martin, Pinni Baumol, Shirelle Noble, Ben Halper
Canadian Psychedelic Survey collected real-world evidence from 2393 Canadian adults on psychedelic use, revealing patterns, effects, and reasons for use. Results may influence policy and treatment approaches.
Philippe Lucas
Psilocybin study shows personality changes and increased self-compassion in alcohol use disorder patients. Larger studies needed to confirm impact on AUD outcomes.
Broc A Pagni
Study investigates psilocybin's effects on depression and burnout in healthcare clinicians post-COVID frontline work with pre- and post-dose psychotherapy. Trial registration: NCT05163496.
Anthony L Back
Clinicians and researchers discuss integrating psilocybin-assisted therapy into serious illness care models, presenting preliminary findings from a pilot study in hospice care for patients with terminal illness.
Yvan Beaussant, Roxanne Sholevar, Lisa Summer, Robin McKenna